| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hoon Jai Chun | |
| Jong-Jae Park | |||
| Moon Kyung Joo | |||
| P2860 | cites work | Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions | Q24187480 |
| Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies | Q27025101 | ||
| 25 Years of Proton Pump Inhibitors: A Comprehensive Review | Q28070003 | ||
| Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis | Q30250237 | ||
| Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multi-drug-resistant variants of cem cells | Q30356063 | ||
| Comparison of Endoscopic Submucosal Dissection and Surgery for Differentiated Type Early Gastric Cancer within the Expanded Criteria | Q33583974 | ||
| Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor | Q33901975 | ||
| Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion | Q34140416 | ||
| STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer | Q34306802 | ||
| Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression | Q34483555 | ||
| The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association | Q34552620 | ||
| Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication | Q34732772 | ||
| The function of the protein tyrosine phosphatase SHP-1 in cancer | Q35092309 | ||
| Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop | Q35741610 | ||
| The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression | Q36179636 | ||
| Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors | Q36187003 | ||
| Proton pump inhibitors and risk of gastric cancer: a population-based cohort study | Q37222668 | ||
| Safety of Proton Pump Inhibitor Exposure | Q37781495 | ||
| Revisiting STAT3 signalling in cancer: new and unexpected biological functions | Q38262473 | ||
| The fight against gastric cancer - the IARC Working Group report | Q38273500 | ||
| Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach | Q38283947 | ||
| Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. | Q38417469 | ||
| Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin | Q38436701 | ||
| Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. | Q38547653 | ||
| TNF-α-inducing protein of Helicobacter pylori induces epithelial-mesenchymal transition (EMT) in gastric cancer cells through activation of IL-6/STAT3 signaling pathway | Q38719059 | ||
| Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells | Q38727019 | ||
| Epigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells | Q38824324 | ||
| Serum gastrin and cholecystokinin are associated with subsequent development of gastric cancer in a prospective cohort of Finnish smokers | Q38860212 | ||
| Signal transducers and activators of transcription 3-induced metastatic potential in gastric cancer cells is enhanced by glycogen synthase kinase-3β. | Q38890455 | ||
| Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition | Q38934990 | ||
| STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma. | Q38953983 | ||
| The PAS positive material in gastric cancer cells of signet ring type is not mucin | Q39019033 | ||
| Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway | Q39105830 | ||
| STAT3 is associated with lymph node metastasis in gastric cancer | Q39130872 | ||
| Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho‑LRP6 expression in Wnt/β-catenin signaling | Q39141497 | ||
| OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells | Q39195889 | ||
| Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. | Q39425929 | ||
| Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells | Q39439324 | ||
| Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. | Q39649432 | ||
| pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity | Q39781678 | ||
| Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells | Q39841916 | ||
| PAI-1 deficiency increases the trophic effects of hypergastrinemia in the gastric corpus mucosa. | Q39869088 | ||
| Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial | Q40046733 | ||
| Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma | Q40258085 | ||
| Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation | Q40604741 | ||
| Regulation of CD44v6 expression in gastric carcinoma by the IL-6/STAT3 signaling pathway and its clinical significance | Q41233768 | ||
| Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes | Q41769227 | ||
| Targeted molecular ablation of cancer stem cells for curing gastrointestinal cancers. | Q41912339 | ||
| Proton-pump inhibitors: understanding the complications and risks | Q41996131 | ||
| Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK | Q42836024 | ||
| Effects of 6-12 months of esomeprazole treatment on the gastric mucosa | Q44485391 | ||
| Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells | Q45205129 | ||
| Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. | Q46270157 | ||
| Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study | Q46476447 | ||
| Proton pump inhibitors may reduce tumour resistance | Q46548498 | ||
| Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up | Q46698299 | ||
| Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial | Q46946129 | ||
| Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden | Q47095023 | ||
| Neuroendocrine differentiation in human gastric carcinoma | Q47741319 | ||
| High salt diets dose-dependently promote gastric chemical carcinogenesis in Helicobacter pylori-infected Mongolian gerbils associated with a shift in mucin production from glandular to surface mucous cells | Q48090212 | ||
| Proton-pump inhibitors and increased gastric cancer risk: time-related biases. | Q48314505 | ||
| Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk | Q49790378 | ||
| Risk factors for gastric cancer: is it time to discard PPIs? | Q50053998 | ||
| Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma. | Q50962433 | ||
| Bidirectional regulation between TMEFF2 and STAT3 may contribute to Helicobacter pylori-associated gastric carcinogenesis. | Q53234855 | ||
| STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. | Q53594652 | ||
| Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. | Q54325125 | ||
| Helicobacter pyloriInfection | Q56157319 | ||
| S1PR1 predicts patient survival and promotes chemotherapy drug resistance in gastric cancer cells through STAT3 constitutive activation | Q57477986 | ||
| Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo | Q57816333 | ||
| Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer | Q58761778 | ||
| A comparison of five maintenance therapies for reflux esophagitis | Q71758935 | ||
| Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells | Q74530718 | ||
| Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group | Q78039842 | ||
| Signet ring cells in gastric carcinomas are derived from neuroendocrine cells | Q81606632 | ||
| Targeting STAT3 in cancer: how successful are we? | Q82824786 | ||
| STAT3 expression in gastric cancer indicates a poor prognosis | Q83254865 | ||
| TMEFF2 deregulation contributes to gastric carcinogenesis and indicates poor survival outcome | Q88202058 | ||
| Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences | Q88935714 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gastroenterology | Q120569 |
| drug resistance | Q12147416 | ||
| antineoplastic resistance | Q13416904 | ||
| proton-pump inhibitor | Q421704 | ||
| stomach neoplasm | Q4335552 | ||
| Helicobacter infection | Q65666252 | ||
| P304 | page(s) | 2058-2070 | |
| P577 | publication date | 2019-05-07 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Proton pump inhibitor: The dual role in gastric cancer | |
| P478 | volume | 25 |
Search more.